On 4/9/18, CNN published an article on the FDA-approved drug, Nuplazid, used to treat hallucinations and A broad medical term used to describe a loss of contact with reality that involves hallucinations and/or delusions. in Parkinson’s disease. The article investigates FDA data showing the number of reported deaths with people taking Nuplazid. Nuplazid was approved by the FDA in 2016 and is manufactured by Acadia Pharmaceuticals.
The Parkinson’s Foundation is closely monitoring the recent reports on Nuplazid. At this time, we are recommending that patients on this drug consult with their neurologists about the risks and benefits of the treatment. The FDA will continue to monitor the drug’s use and safety, but they have not identified a specific safety issue that isn’t already described in the drug’s label.
Parkinson’s disease psychosis is typically seen in advanced stages of Parkinson’s disease involving elderly patients. Treating Parkinson’s disease psychosis is a multi-step process that begins with talking to your health care team. They will follow a series of steps to figure out how best to address symptoms. For more information on this topic, please call our toll-free Helpline at 1-800-4PD-INFO (473-4636).
Please report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088. You can also call ACADIA Pharmaceuticals Inc. at 1‑844‑4ACADIA (1‑844‑422‑2342).
For more information about Psychosis and Parkinson’s Disease: